- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01948817
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
A Prospective Single Arm Study to Assess the Efficacy and Safety of Deferasirox 20 mg/kg BID in Transfusion Dependent Thalassemia Patients Inadequately Responding to Current Treatment With Doses > 35mg/kg QD (Once a Day).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Study treatment is defined as deferasirox 20 mg/kg BID. The study treatment duration is 24 weeks. After the baseline visit, patient visits will occur weekly during the first month because key safety parameters need to be performed weekly in the first month of treatment and then every 4 weeks thereafter until week 24 End of Treatment (EOT).
Patients will have their first dose of study treatment at Visit 3. Safety assessments are routinely performed including collection of AEs (Adverse Events), SAEs (Serious ADverse Events<, vital signs, physical examination, ECG (Electrocardiograph), hematological and biochemistry assessments.
Patients will continue therapy until intolerable toxicity, patient decision or after 24 weeks treatment duration at which point and End of Treatment (EOT) visit will be performed and the End of Treatment CRF( Case Report Form) will be completed.
30 day Safety follow-up Patients who discontinue study drug before completing the study should be scheduled for a visit as soon as possible, at which time all of the assessments listed for the final visit will be performed. At a minimum, all patients who discontinue study treatment, including those who refuse to return for a final visit, will be contacted for safety evaluations during the 30 days following the last dose of study drug.
All patients must be followed for AEs and SAEs that may have occurred after discontinuation from the study treatment. The safety follow-up visit will take place 30 days after the last dose of study drug.
Tipo de estudio
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent must be obtained prior to any screening procedures
- Male or female aged ≥ 2 years at screening
- Patients with transfusion dependent thalassemia
- Patients confirmed as inadequate- responders to deferasirox > 35 mg/kg QD and treated with QD for at least 6 months
- Regular transfusion indicated by a blood requirement ≥ 8 blood transfusions per year at screening
- Serum ferritin level > 2,500 ng/mL at screening (two consecutive values at least 2 weeks apart from each other)
- One SF measurement > 2,500 ng/mL between 6 and 9 months prior to study enrollment
- Three SF measurements > 2,500 ng/mL, performed at least 3 weeks apart from each other, during the 6 month treatment with QD dosing of deferasirox prior to study enrollment
- The average of the two screening SF values (collected 2 weeks apart from each other) must not show a decrease from the 6 to 9 month SF value taken prior to study enrollment
- The average of the two screening SF values (collected 2 weeks apart from each other) must not show a decrease from each of the three SF values obtained during the 6 months of deferasirox QD treatment prior to study enrollment
- LIC ≥ 7 mg Fe/g dw measured at the screening visit, (this value will be used as a baseline measurement
Exclusion Criteria:
- Patients who are intolerant to > 35 mg/kg/day QD of deferasirox in the 6 months prior to study enrollment
- Patients with mean levels of ALT >5 x ULN
- Patients with serum creatinine above the upper limit of normal (ULN)
- Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 (mg/mg)
- Creatinine clearance ≤ 60 ml/min
- Chronic hepatitis B infection, active hepatitis C infection
- History of a positive HIV test
- Uncontrolled systemic hypertension
- Patients participating in another clinical trial or receiving a systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days of screening
- History of non-compliance with medical regimens or patients who are considered potentially unreliable and/or not cooperative, unwilling or unable to comply with the protocol
- History of hypersensitivity to any of the study drug or excipients
- Significant medical condition interfering with the ability to partake in this study (e.g. systemic uncontrolled hypertension, unstable cardiac disease not controlled by standard medical therapy, systemic disease (cardiovascular, renal, hepatic etc.)
- History of drug or alcohol abuse within the 12 months prior to enrollment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Deferasirox
Deferasirox 20mg/kg taken BID
|
Deferasirox 20mg/kg taken BID
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Mean relative change in SF (Serum Ferritin)
Periodo de tiempo: Baseline, 24 Weeks
|
To evaluate the efficacy of a twice-daily dose regimen of deferasirox in inadequate-responders to a once daily dose regimen as measured by relative change in serum ferritin from baseline to 24 weeks of treatment
|
Baseline, 24 Weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Mean Absolute/relative change in LIC
Periodo de tiempo: Baseline, 24 Weeks
|
To evaluate the efficacy of BID deferasirox in liver iron removal as measured by MRI by absolute/relative change from baseline to 24 weeks of treatment
|
Baseline, 24 Weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CICL670A2420
- 2013-002624-16 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Deferasirox
-
Novartis PharmaceuticalsTerminadoAnemia dependiente de transfusionesEgipto, Hungría, Pavo, Estados Unidos, Bulgaria, Italia, Bélgica, Federación Rusa, Filipinas, Francia, Malasia, India, Omán, Panamá, Líbano, Tailandia, Túnez
-
DisperSol Technologies, LLCTerminado
-
Novartis PharmaceuticalsTerminadoTalasemia no dependiente de transfusiones | Talasemia dependiente de transfusionesEgipto, Pavo, Tailandia, Líbano, Marruecos, Arabia Saudita, Vietnam
-
Novartis PharmaceuticalsRetiradoTalasemia (Transfusión Delendent)
-
Novartis PharmaceuticalsTerminadoSíndrome mielodisplásico de riesgo bajo e int 1Alemania, Canadá, Corea, república de, Suecia, España, Porcelana, Argentina, Italia, Reino Unido, Argelia
-
Assistance Publique - Hôpitaux de ParisAssociation pour l'Etude des Fonctions Digestives (AEFD)DesconocidoPorfiria Cutánea TardaFrancia
-
Novartis PharmaceuticalsTerminadoHemosiderosis transfusional | Sobrecarga transfusional de hierroTaiwán, Pavo, Egipto, Reino Unido, Tailandia, Canadá, Porcelana, Italia, Chipre, Líbano, Emiratos Árabes Unidos
-
NovartisTerminadoBeta-talasemia | HemosiderosisEgipto, Líbano, Omán, Arabia Saudita, República Árabe Siria
-
Novartis PharmaceuticalsTerminadoTalasemia no dependiente de transfusionesTailandia, Pavo, Italia, Grecia, Porcelana, Reino Unido, Líbano, Túnez
-
City of Hope Medical CenterTerminadoMielofibrosis primaria | Mieloma múltiple en estadio I | Mieloma múltiple en estadio II | Mieloma múltiple en estadio III | Sobrecarga de hierro | Leucemia mielomonocítica crónica | Leucemia mieloide aguda recurrente en adultos | Linfoma de células B de la zona marginal extraganglionar del tejido... y otras condicionesEstados Unidos